Guest column

Why this Italian tech company is betting on Houston

An Italian company has moved in on Houston. In an op-ed, the company's founder shares why he bet on the Bayou City. Photo via Getty Images

Earlier this year, I opened my company's U.S. headquarters and became an Italian transplant in Houston.

After establishing my additive manufacturing business in my home country, the company thrived in Europe and we began evaluating foreign markets to support our expansion. We considered several cities in North America and will likely establish operations in some of these regions in the coming years, but one thing will remain unchanged – our commitment to naming Houston the command post of our operations.

I have ambitious plans that Houston is uniquely positioned to address. Over the next 24 months, we expect to hire more than 100 employees to reshore domestic production, decrease carbon emissions, and mitigate supply chain challenges using super polymers in our 3D printing production system.

In order to meet these objectives, I am leveraging the city's business-friendly environment and thriving, international community to support several core industries, including energy, aerospace, medtech and transportation and logistics.

Convergence of Tech, Industry and Talent 

Across the world, Houston has long been known as the energy capital of the world. Over time, it is adapting a new image – one that unites all the prominent industries – a thriving tech hot spot. With cultural ties around the world, I am excited to immerse our team in industry events and take advantage of our proximity to exciting scientific initiatives, boundary-pushing engineers, new and existing customers, and renowned universities.

The city has been teeming with several tech giants who are driving the Texas tech boom after realizing the opportunities that also caught my attention. The tremendous increase in corporate relocations and expansions in Texas have shined a spotlight on Houston.

The evolution also highlights the opportunities the city presents for young engineers and recent college graduates chasing careers in evolving areas like advanced manufacturing, aerospace, and medtech. As I expand my engineering and production capabilities, I am captivated by the highly specialized and ever-growing workforce in legacy and emerging industries.

Building a More Sustainable Future and Revitalizing American Manufacturing 

As I get to know the local businesses making up the area, I am also discovering the ways in which Houston is playing a role in building the infrastructure that is advancing a more sustainable future. This joint effort, led by local businesses, educational institutions, policies, and people, leverages the technologies developed by stateside experts and attracting foreign executives, like myself, who bring fresh perspectives and solutions to accelerate our vision for the future.

At my company, for example, we are introducing technology to contribute to the global energy transition, incorporating more sustainable materials into production workflows to reduce industrial emissions. Through maturing printing networks in the region, manufacturers can print "parts on demand" whenever and wherever needed, which can reduce or eliminate the need to warehouse infrequently used parts as well as reliance on slower, more expensive traditional fabrication often located overseas.

As I immerse myself in the city's growing tech ecosystem, I am excited to play a role in building the additive manufacturing industry in Houston.

------

Alessio Lorusso is founder and CEO of Roboze.

Trending News

Building Houston

 
 

Five companies have been selected for a brand new accelerator program in Houston. Image via Getty Images

A Houston medical technology organization has announced the inaugural cohort of a new early-stage accelerator.

M1 MedTech, launched this year by Houston-based Proxima Clinical Research, announced its Fall 2022 cohort.

“This initial cohort launches M1 MedTech with an interactive 14-week agenda covering the basics every emerging MedTech business needs to progress from a startup to an established solution in their market,” says Sean Bittner, director of programs at M1 MedTech, in a news release.

The accelerator will equip early-stage startups with storytelling, business plan support, investor connections, FDA guidance, research, and more through one-on-one consultations, workships, and in-kind services.

The first cohort includes five startups, per the release from the company:

  1. Linovasc. Providing a long overdue major update to balloon angioplasty devices in over 50 years, the Linovasc solution offers a safer branch occlusion and aortic stent dilatation using a toroidal balloon that expands the aorta uniformly without the ischemia caused by current treatments. The company is founded by Bruce Addis.
  2. Grapheton. Founded by Sam Kassegne and Bao Nguyen, Grapheton's patented carbon materials work with electrically active devices to improve the longevity and outcome of bioelectric implants in the body. Terry Lingren serves as the CEO of the startup.
    • Rhythio Medical. Founded by Kunal Shah and Savannah Esteve, Rhythio is the first preventative approach to heart arrhythmias.The chief medical officer is Dr. Mehdi Razavi.
      • PONS Technology. An AI cognitive functioning ultrasound device attempting to change the way ultrasound is done, PONS is founded by CEO: Soner Haci and CTO: Ilker Hacihaliloglu.
        • Vivifi Medical. Founded by CEO Tushar Sharma, Vivifi is the first suture-less laparoscopic technology that connects vessels to improve male infertility and benign prostatic hyperplasia. The company's senior R&D engineer is Frida Montoya.

          The program includes support from sponsors and experts from: Proxima Clinical Research, Greenlight Guru, Medrio, Galen Data, Merge Medical Device Studio, Venn Negotiation, Engagement PR & Marketing, Aleberry Creative, and others.

          “This is an amazing opportunity for emerging founders to learn the progression of pipelining their ideas through the FDA and absorb the critical strategies for success early in their business development,” says Isabella Schmitt, principal at M1 MedTech and director of regulatory affairs at Proxima CRO, in the release.

          Trending News